MedTrace Logo

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

NCT00490906 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2014-01-22

No results posted yet for this study

Summary

The purpose of this study is to determine if certain drugs commonly used to treat multiple sclerosis have an effect on bone health.

Conditions

Interventions

DRUG

Copaxone

20 mg, subcutaneous injections, taken daily

DRUG

Interferon-beta 1a

30 mcg injected intramuscularly, once weekly

DRUG

Interferon-beta 1b

.25 mg/day, taken every other day, subcutaneous injections

Sponsors & Collaborators

  • Kansas City Area Life Sciences Institute, Inc.

    collaborator OTHER

  • Nancy Hammond, MD

    lead OTHER

Principal Investigators

  • Nancy Hammond, MD · University of Kansas Medical Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-02-28
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00490906 on ClinicalTrials.gov